VP-301 is under clinical development by Virtuoso Therapeutics and currently in Phase I for Refractory Multiple Myeloma. According to GlobalData, Phase I drugs for Refractory Multiple Myeloma have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how VP-301’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

VP-301 overview

VP-301 is under development for the treatment of relapsed and refractory multiple myeloma, lymphoma and solid tumors. The therapeutic candidate is a bi-specific monoclonal antibody. It acts by targeting CD38 and intercellular adhesion molecules-1 (ICAM-1).

Virtuoso Therapeutics overview

Virtuoso Therapeutics specializes in developing the therapies for the cancer treatment. Virtuoso Therapeutics is headquartered in San Mateo, California, the US.

For a complete picture of VP-301’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.